Schedule Dispatches

Schedule dispatches give a summary of changes coming out in the next month.

This is an early notification of the changes to be announced in the Update to the Pharmaceutical Schedule.

The full Update is available as a PDF(external link)

The changes will be published in the online Schedule around the 23rd of this month and are effective from next month.

For any questions about these listing changes or the Pharmaceutical Schedule in general, email us at enquiry@pharmac.govt.nz

16 May 2025 | June 2025 Pharmaceutical Schedule Dispatch

New Listings

  • Dabrafenib (Tafinlar) cap 50 mg (p’code 2483270) and cap 75 mg (p’code 2483289) – Special Authority-Retail Pharmacy
  • Ethosuximide (Zarontin) cap 250 mg (p’code 2705117)
  • Famotidine (Famotidine Hovid MY) tab 40 mg – section 29 and wastage claimable (p’code 2706229)
  • Haemophilus influenzae type B vaccine (Act-HIB) inj 10 mcg vial diluent syringe – only on a prescription, no patient co-payment payable and funding criteria applies (p’code 2697955)
  • Ipratropium bromide (Accord) nebuliser soln, 250 mcg per ml, 2 ml ampoule – up to 40 neb available on a PSO, section 29 and wastage claimable (p’code 2643154)
  • Propranolol (Hikma-Propranolol) oral liq 4 mg per ml, 500 ml – Special Authority-Retail Pharmacy, section 29 (p’code 2681080)
  • Sotalol (Sotalol Viatris) tab 80 mg – section 29 and wastage claimable (p’code 2703580)
  • Trametinib (Mekinist) tab 0.5 mg (p’code 2483254) and 2 mg (p’code 2483262) – Special Authority-Retail Pharmacy
  • Zoledronic acid (Zoledronic acid Viatris S29) inj 4 mg per 5 ml, vial – section 29 and wastage claimable (p’code 2706032)

Changes to restrictions, chemical names and presentations

  • Ambrisentan (Ambrisentan Viatris) tab 5 mg and 10 mg – amended Special Authority criteria
  • Dasatinib (Dasatinib Teva) tab 20 mg, 50 mg and 70 mg – removal of brand switch fee
  • Glycerin with sodium saccharin (Ora-Sweet SF) suspension, 437 ml – removal of note
  • Glycerin with sucrose (Ora-Sweet) suspension, 437 ml – removal of note
  • Infliximab inj 100 mg (Remicade) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
  • Nivolumab inj 10 mg per ml, 4 ml and 10 ml vial (Opdivo) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
  • Pembrolizumab inj 25 mg per ml, 4 ml vial (Keytruda) and inj 1 mg for ECP (Baxter) – amended Special Authority criteria
  • Phytomenadione (Konakion MM Paediatric) inj 2 mg per 0.2 ml – amended brand name
  • Prochlorperazine (Prochlorperazine maleate (Brown & Burk)) tab 3 mg buccal – amended brand name
  • Renal oral feed 1.8 kcal/ml (Nepro HP (strawberry) and Nepro HP (vanilla)) liquid, 220 ml bottle – amended presentation description
  • Secukinumab (Cosentyx) inj 150 mg per ml, 1 ml prefilled syringe – amended Special Authority criteria
  • Tocilizumab inj 20 mg per ml, 4 ml vial, 10 ml vial and 20 ml vial (Actemra) and inj 1 mg ECP (Baxter) – amended Special Authority criteria 

Increased subsidy

Chemical

Presentation

Fully subsidised brands

Lithium carbonate

Cap 250 mg

Douglas

Find older dispatches